 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
CryoLife, Inc. (CRY) manufactures and distributes medical devices worldwide.
It also processes and distributes implantable human tissues for use in cardiac and vascular surgeries. The company operates in two segments, Medical Devices and Preservation Services.
It offers surgical sealants and hemostats, including BioGlue Surgical Adhesive, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; BioFoam Surgical Matrix, which is used as an adjunct in sealing abdominal parenchymal tissues, as well as an adjunct for hemostasis in cardiovascular surgery; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
The company also provides cardiac laser therapy products, which include laser console system and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina; and On-X heart valves for aortic and mitral indications.
In addition, it distributes ProCol vascular bioprosthesis, a biological graft that provides vascular access for end-stage renal disease in hemodialysis patients; and PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities. Further, it distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using its proprietary SynerGraft technology; and vascular preservation services, such as CryoVein and CryoArtery tissues to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections.
The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons.
Shares of this company have formed a bullish "flag" following the company's recent earnings report. The company reported revenues of $47.08 million, and Net Earnings of $2.30 million or a loss of 2 cents per share. Gross margins jumped to 61.90% from 59.26%. Higher share prices are expected for this stock.
52-Weeks Trading Range: $8.94 - $14.80
Entry Point: $15.00
Stop Loss: $14.00
Target Price: $16.55
CRY closed at $16.98.
